Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy
ReutersAug 18, 2025 2:25 PM
Aug 18 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O:
ULTRAGENYX INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR DTX401 AAV GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)
ULTRAGENYX PHARMACEUTICAL INC - PLANS TO COMPLETE FULL BLA SUBMISSION IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.TradingKey
8 hours ago
Figma (FIG): Beyond the Hype and the Flashy News Articles
TradingKey - There are certain aspects of Figma (FIG) that demonstrate the solid foundation they have – deep penetration of Fortune 500 clients, record-high gross margins, and still early stage of monetization. However, the competitive landscape is quite hard to predict with big incumbentsTradingKey
10 hours ago
Eurozone July HICP Preview: ECB Likely to Continue Rate Cuts
TradingKey - On 20 August 2025, the Eurozone will release its July Harmonised Index of Consumer Prices (HICP) data. Market consensus anticipates the headline HICP to rise by 2% year-on-year, with the core HICP increasing by 2.3% year-on-year, both unchanged from the previous month. Since the start..TradingKey
12 hours ago
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
13 hours ago
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
Thu, Aug 14
